Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Prepaid Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Prepaid Assets for 6 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 83.84% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 83.84% increase, with the full-year FY2025 number at $4.8 million, up 83.84% from a year prior.
  • Prepaid Assets was $4.8 million for Q4 2025 at TScan Therapeutics, up from $3.7 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $5.3 million in Q1 2023 to a low of $1.4 million in Q2 2023.
  • A 5-year average of $3.4 million and a median of $3.7 million in 2025 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: soared 156.89% in 2021, then plummeted 63.43% in 2024.
  • TScan Therapeutics' Prepaid Assets stood at $4.2 million in 2021, then dropped by 3.51% to $4.1 million in 2022, then crashed by 46.51% to $2.2 million in 2023, then rose by 19.11% to $2.6 million in 2024, then surged by 83.84% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Prepaid Assets are $4.8 million (Q4 2025), $3.7 million (Q3 2025), and $3.1 million (Q2 2025).